Phibro Animal Health Corporation reports developments in animal health, mineral nutrition and performance products for food-animal markets. The company develops, manufactures and markets antibacterials, anticoccidials, nutritional specialty products, vaccines and mineral nutrition products for poultry, swine, beef and dairy cattle, and aquaculture in the United States and international markets.
Recurring PAHC news includes quarterly results and guidance, cash dividend declarations on Class A and Class B common stock, investor conference participation and regulatory updates affecting antimicrobial products such as virginiamycin and bacitracin. Company updates also address product portfolio activity, acquisition-related effects, input and distribution costs, foreign-currency impacts and tools such as PhibroVet for veterinary prescription management.
Phibro Animal Health (Nasdaq: PAHC) reported first-quarter net sales of $386.8 million and maintained its fiscal 2027 financial guidance.
For the quarter ended September 30, 2026, sales rose 6%, net income increased 11% to $29.5 million and diluted earnings per share rose 11% to $0.72. Adjusted EBITDA rose 4% to $64.3 million; this measure excludes interest, taxes, depreciation, amortization and specified adjustments. Animal Health sales grew 3%, Mineral Nutrition 17% and Performance Products 16%. Operating income fell 3% to $49.6 million as selling, general and administrative expenses increased 15%.
For the year ending June 30, 2027, Phibro expects sales of $1.55 billion–$1.60 billion, net income of $122 million–$132 million and adjusted EBITDA of $258 million–$268 million, assuming no additional virginiamycin sales in Brazil for the remainder of the fiscal year. Total debt was $739.6 million at September 30.
Phibro Animal Health (Nasdaq: PAHC) declared a quarterly cash dividend of $0.12 per share on its common stock. The dividend covers both Class A and Class B common stock and is payable on December 16, 2026, to stockholders of record at the close of business on November 25, 2026.
Phibro Animal Health (PAHC) expects to announce its first-quarter financial results on November 4, 2026, after the market closes. Management will host a conference call and webcast on November 5, 2026, at 9:00 AM Eastern Time. Presentation slides and the webcast will be accessible through the investor website, with a replay available approximately two hours after the live event concludes.
Phibro Animal Health (PAHC) will participate in the Morgan Stanley Annual Global Healthcare Conference. President and CEO Daniel Bendheim, COO Larry Miller, and CFO Glenn David will address financial analysts and investors on Tuesday, September 15, 2026, at 1:05 PM ET at the New York Marriott Marquis in New York.
A live audio presentation will be accessible via the company’s Investor Relations website, with a replay archived on the company’s website after the event.
Phibro Animal Health (Nasdaq: PAHC) reported fourth quarter 2026 net sales of $396.7 million, up 5% year over year, with net income of $21.7 million, up 26%, and adjusted EBITDA of $64.2 million, up 29%. Adjusted diluted EPS rose 35% to $0.85. Gross margin for the quarter expanded 490 basis points to 33.9%, aided by favorable mix and a $4.3 million tariff recovery benefit.
For fiscal 2026, net sales increased 17% to $1,518.1 million and net income rose to $99.7 million, with adjusted EBITDA up 39% to $255.0 million and adjusted diluted EPS up 48% to $3.22. Phibro issued fiscal 2027 guidance for net sales of $1.55–$1.60 billion, adjusted EBITDA of $258–$268 million, and adjusted net income of $140–$147 million. The company plans to close its Chicago Heights manufacturing facility by summer 2027, affecting about 100 employees, and will shift production to other sites and contract manufacturers.
Phibro Animal Health (Nasdaq: PAHC) plans to release its fourth quarter and fiscal year 2026 financial results on Wednesday, August 26, 2026, after market close. Management will host a conference call and webcast on Thursday, August 27, 2026, at 9:00 AM Eastern Time, accessible via the company’s investor website or designated phone lines.
Phibro Animal Health (Nasdaq: PAHC) announced that its Board of Directors has declared a quarterly cash dividend of $0.12 per share on both its Class A and Class B common stock. The dividend is payable on September 23, 2026 to shareholders of record as of September 2, 2026.
Phibro Animal Health (Nasdaq: PAHC) will participate in the Stifel Jaws & Paws Conference on May 27, 2026, at 9:45 AM ET in New York.
Senior executives will address analysts and investors, with a live audio webcast and replay available on the company’s investor relations website.
Phibro Animal Health (Nasdaq: PAHC) will present at the Bank of America Securities Health Care Conference on May 13, 2026 at 1:40 PM ET in Las Vegas. Executives Daniel Bendheim, Larry Miller and Glenn David will address analysts and investors. A live audio webcast and archived replay will be available on the company investor site.
Phibro Animal Health (Nasdaq: PAHC) reported Q3 FY2026 results: net sales $383.5M (+10%), net income $24.0M (+15%), adjusted EBITDA $60.8M (+11%) and adjusted diluted EPS $0.76 (+19%).
The company updated FY2026 guidance to $1.46B–$1.50B net sales and $247M–$255M adjusted EBITDA, and expanded its revolving credit facility by $125M.